IQVIA Holdings (IQV) Draws Undervalued Attention, Is The Recent Momentum Fully Priced In?

IQVIA Holdings (IQV) has drawn investor attention after recent share price moves, with the stock last closing at US$203.79. The company now carries an equity value of about US$34.75b in the healthcare data and research space.

See our latest analysis for IQVIA Holdings.

Recent trading has been choppy for IQVIA Holdings, with the share price falling 2.13% over the last day but gaining 10.94% over 1 month and 20.60% over 3 months. The 1 year total shareholder return of 25.78% contrasts with weaker 3 and 5 year total shareholder returns, which hints that momentum has picked up recently after a tougher multi year period.

If IQVIA’s recent moves have you rethinking where growth could come from in healthcare data, it may be worth widening your screen to include 40 healthcare AI stocks

IQVIA looks like a heavyweight in clinical research and healthcare data, and the recent 3 month gain of 20.60% has sharpened interest. The real test now is whether IQVIA’s current price still offers value.

Most Popular Narrative: 10.2% Undervalued

IQVIA Holdings is trading at $203.79 against a widely followed fair value estimate of about $226.95, which frames the stock as modestly undervalued on this narrative and sets up a case built around data, AI and clinical research demand.

Accelerated adoption of AI-driven analytics and data solutions, supported by strong client demand and high-profile industry partnerships like NVIDIA, positions IQVIA for improved operational efficiency, faster project execution, and differentiation, which should support future revenue growth and eventual margin expansion as AI capabilities scale.

Read the complete narrative.

There is a detailed playbook sitting behind that valuation. It blends steady top line expansion, firmer margins and a specific earnings path over several years. Curious how that mix of growth, profitability and assumed valuation multiple is wired together to reach this fair value?

Result: Fair Value of $226.95 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, IQVIA’s story could change if CRO pricing pressure intensifies, or if high leverage and refinancing needs start to weigh more heavily on earnings and flexibility.

Find out about the key risks to this IQVIA Holdings narrative.

Next Steps

Given the mix of optimism and caution around IQVIA Holdings, it makes sense to look under the hood yourself and not just follow the crowd. To pressure test your own thesis quickly, weigh up the company’s 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond IQVIA Holdings?

If IQVIA Holdings has sharpened your interest in what is possible, do not stop here. Broaden your watchlist now with other focused stock ideas.

• Explore potential opportunities in smaller companies that already show financial strength by scanning the 20 elite penny stocks with strong financials.
• Focus on companies that pair quality with pricing that may look appealing using the 44 high quality undervalued stocks.
• Prioritise stability and balance sheet strength by screening with the solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.